{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:57:48Z","timestamp":1791248268487,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006967","name":"Center for AIDS Research, Duke University","doi-asserted-by":"publisher","award":["5P30 AI064518"],"award-info":[{"award-number":["5P30 AI064518"]}],"id":[{"id":"10.13039\/100006967","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"DOI":"10.1007\/s10461-026-05319-8","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:43:43Z","timestamp":1791247423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Perspectives on Leveraging Long-Acting Injectable Antiretroviral Therapy Visits to Improve Chronic Disease Care"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-4615","authenticated-orcid":false,"given":"Emily D.","family":"Niehaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Muiruri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Corneli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nwora Lance","family":"Okeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"5319_CR1","unstructured":"Administration FD. Cabenvua and Vocabria approved for HIV infection: U.S. food and drug administration; 2021 [Available from: https:\/\/www.fda.gov\/drugs\/human-immunodeficiency-virus-hiv\/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection."},{"issue":"2","key":"5319_CR2","first-page":"75","volume":"40","author":"S Rusconi","year":"2017","unstructured":"Rusconi S, Marcotullio S, Cingolani A. Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient\u2019s perspective. New Microbiol. 2017;40(2):75\u20139.","journal-title":"New Microbiol"},{"issue":"3","key":"5319_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106627","volume":"60","author":"S Rusconi","year":"2022","unstructured":"Rusconi S, Santoro MM, Capetti AF, Gianotti N, Zazzi M. The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions. Int J Antimicrob Agents. 2022;60(3):106627.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"5319_CR4","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2217\/nnm.12.214","volume":"8","author":"J Williams","year":"2013","unstructured":"Williams J, Sayles HR, Meza JL, Sayre P, Sandkovsky U, Gendelman HE, et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine. 2013;8(11):1807\u201313.","journal-title":"Nanomedicine"},{"key":"5319_CR5","doi-asserted-by":"publisher","first-page":"232595822098126","DOI":"10.1177\/2325958220981265","volume":"19","author":"DE Koren","year":"2020","unstructured":"Koren DE, Fedkiv V, Zhao H, Kludjian G, Bettiker RL, Tedaldi E, et al. Perceptions of long-acting injectable antiretroviral treatment regimens in a united states urban academic medical center. J Int Assoc Provid AIDS Care. 2020;19:2325958220981265.","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"3","key":"5319_CR6","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1016\/S2352-3018(22)00031-5","volume":"9","author":"JC Hojilla","year":"2022","unstructured":"Hojilla JC, Gandhi M, Satre DD, Johnson MO, Saberi P. Equity in access to long-acting injectables in the USA. Lancet HIV. 2022;9(3):e145-7.","journal-title":"Lancet HIV"},{"issue":"12","key":"5319_CR7","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1097\/QAD.0000000000001870","volume":"32","author":"TG Harris","year":"2018","unstructured":"Harris TG, Rabkin M, El-Sadr WM. Achieving the fourth 90: healthy aging for people living with HIV. AIDS. 2018;32(12):1563\u20139.","journal-title":"AIDS"},{"issue":"12","key":"5319_CR8","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1097\/QAD.0000000000003000","volume":"35","author":"ER Weinstein","year":"2021","unstructured":"Weinstein ER, Lee JS, Mendez NA, Harkness A, Safren SA, El-Sadr W. HIV\/AIDS and aging: the new frontier for HIV\/AIDS research and care. AIDS. 2021;35(12):2043\u20135.","journal-title":"AIDS"},{"issue":"1","key":"5319_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jama.2019.19775","volume":"323","author":"AM Lerner","year":"2020","unstructured":"Lerner AM, Eisinger RW, Fauci AS. Comorbidities in persons With HIV: the lingering challenge. JAMA. 2020;323(1):19\u201320.","journal-title":"JAMA"},{"issue":"10","key":"5319_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186638","volume":"12","author":"M Smit","year":"2017","unstructured":"Smit M, Cassidy R, Cozzi-Lepri A, Quiros-Roldan E, Girardi E, Mammone A, et al. Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: a modelling study. PLoS ONE. 2017;12(10):e0186638.","journal-title":"PLoS ONE"},{"issue":"1","key":"5319_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004325","volume":"21","author":"KN Althoff","year":"2030","unstructured":"Althoff KN, Stewart C, Humes E, Gerace L, Boyd C, Gebo K, et al. The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: a modeling study. PLoS Med. 2030;21(1):e1004325.","journal-title":"PLoS Med"},{"issue":"8","key":"5319_CR12","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1080\/03007995.2022.2088714","volume":"38","author":"M Paudel","year":"2022","unstructured":"Paudel M, Prajapati G, Buysman EK, Goswami S, Mao J, McNiff K, et al. Comorbidity and comedication burden among people living with HIV in the United States. Curr Med Res Opin. 2022;38(8):1443\u201350.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"5319_CR13","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","volume":"138","author":"ASV Shah","year":"2018","unstructured":"Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018;138(11):1100\u201312.","journal-title":"Circulation"},{"issue":"2","key":"5319_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/QAD.0000000000003420","volume":"37","author":"R Lang","year":"2023","unstructured":"Lang R, Hogan B, Zhu J, McArthur K, Lee J, Zandi P, et al. The prevalence of mental health disorders in people with HIV and the effects on the HIV care continuum. AIDS. 2023;37(2):259\u201369.","journal-title":"AIDS"},{"key":"5319_CR15","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.5888\/pcd10.120083","volume":"10","author":"KA Lichtenstein","year":"2013","unstructured":"Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi E, et al. Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients. Prev Chronic Dis. 2013;10:E10.","journal-title":"Prev Chronic Dis"},{"issue":"6","key":"5319_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1071\/SH13009","volume":"10","author":"D Chan","year":"2013","unstructured":"Chan D, Gracey D, Bailey M, Richards D, Dalton B. Screening and management of cardiovascular disease in Australian adults with HIV infection. Sex Health. 2013;10(6):495\u2013501.","journal-title":"Sex Health"},{"key":"5319_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/tbm\/ibab125","author":"KI Galaviz","year":"2021","unstructured":"Galaviz KI, Colasanti JA, Kalokhe AS, Ali MK, Ofotokun I, Fernandez A. Factors associated with adherence to guideline-recommended cardiovascular disease prevention among HIV clinicians. Transl Behav Med. 2021. https:\/\/doi.org\/10.1093\/tbm\/ibab125.","journal-title":"Transl Behav Med"},{"issue":"22","key":"5319_CR18","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1093\/ajhp\/zxac224","volume":"79","author":"K Gallegos Aragon","year":"2022","unstructured":"Gallegos Aragon K, Ray G, Conklin J, Stever E, Marquez C, Magallanes A, et al. Underprescribing of statin therapy in people with HIV at risk for atherosclerotic cardiovascular disease. Am J Health Syst Pharm. 2022;79(22):2026\u201331.","journal-title":"Am J Health Syst Pharm"},{"key":"5319_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007107","author":"JA Ladapo","year":"2017","unstructured":"Ladapo JA, Richards AK, DeWitt CM, Harawa NT, Shoptaw S, Cunningham WE, et al. Disparities in the quality of cardiovascular care between HIV-infected versus HIV-uninfected adults in the United States: a cross-sectional study. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/JAHA.117.007107.","journal-title":"J Am Heart Assoc"},{"key":"5319_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ahj.2018.11.012","volume":"209","author":"RA Riestenberg","year":"2019","unstructured":"Riestenberg RA, Furman A, Cowen A, Pawlowksi A, Schneider D, Lewis AA, et al. Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons. Am Heart J. 2019;209:79\u201387.","journal-title":"Am Heart J"},{"issue":"11","key":"5319_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-054629","volume":"11","author":"S Singh","year":"2021","unstructured":"Singh S, Kirk O, Jaffar S, Karakezi C, Ramaiya K, Kallestrup P, et al. Patient perspectives on integrated healthcare for HIV, hypertension and type 2 diabetes: a scoping review. BMJ Open. 2021;11(11):e054629.","journal-title":"BMJ Open"},{"key":"5319_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/PPA.S287325","volume":"15","author":"L Mkumba","year":"2021","unstructured":"Mkumba L, Muiruri C, Garg K, Watt MH, Okeke NL. Perspectives of chronic disease management among persons with HIV: a qualitative study. Patient Prefer Adherence. 2021;15:49\u201355.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"5319_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s43058-021-00114-z","volume":"2","author":"J Schexnayder","year":"2021","unstructured":"Schexnayder J, Longenecker CT, Muiruri C, Bosworth HB, Gebhardt D, Gonzales SE, et al. Understanding constraints on integrated care for people with HIV and multimorbid cardiovascular conditions: an application of the theoretical domains framework. Implement Sci Commun. 2021;2(1):17.","journal-title":"Implement Sci Commun"},{"key":"5319_CR24","doi-asserted-by":"crossref","unstructured":"Gausi B OP, Jacob N, Oni T. Patient outcomes in integrated HIV and non-communicable disease models of care: a scoping review. J Global Health Rep. 2021.","DOI":"10.29392\/001c.27094"},{"issue":"2","key":"5319_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/sextrans-2016-052643","volume":"93","author":"AH Miners","year":"2017","unstructured":"Miners AH, Llewellyn CD, Cooper VL, Youssef E, Pollard AJ, Lagarde M, et al. A discrete choice experiment to assess people living with HIV\u2019s (PLWHIV\u2019s) preferences for GP or HIV clinic appointments. Sex Transm Infect. 2017;93(2):105\u201311.","journal-title":"Sex Transm Infect"},{"issue":"1","key":"5319_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/QCO.0000000000000890","volume":"36","author":"P Collini","year":"2023","unstructured":"Collini P, Mawson RL. A new era of HIV care for age-associated multimorbidity. Curr Opin Infect Dis. 2023;36(1):9\u201314.","journal-title":"Curr Opin Infect Dis"},{"key":"5319_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf096","author":"E Ochieng","year":"2025","unstructured":"Ochieng E, Robinson V, Anderson E, Niles-Carnes L, Smith BL, Armstrong WS, et al. Enhancing Hepatitis B virus vaccine uptake and immunity through long-acting antiretroviral therapy programmatic synergy in the US South. Open Forum Infect Dis. 2025. https:\/\/doi.org\/10.1093\/ofid\/ofaf096.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"5319_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-023-00418-6","volume":"18","author":"KJ Langdon","year":"2023","unstructured":"Langdon KJ, Hitch AE, Collins AB, Beckwith CG, Becker S, Tashima K, et al. Integrating long-acting injectable treatment to improve medication adherence among persons living with HIV and opioid use disorder: study protocol. Addict Sci Clin Pract. 2023;18(1):60.","journal-title":"Addict Sci Clin Pract"},{"issue":"4","key":"5319_CR29","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G","volume":"23","author":"M Sandelowski","year":"2000","unstructured":"Sandelowski M. Whatever happened to qualitative description? Res Nurs Health. 2000;23(4):334\u201340.","journal-title":"Res Nurs Health"},{"issue":"6","key":"5319_CR30","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/0272989X08327068","volume":"28","author":"JO Prochaska","year":"2008","unstructured":"Prochaska JO. Decision making in the transtheoretical model of behavior change. Med Decis Making. 2008;28(6):845\u20139.","journal-title":"Med Decis Making"},{"key":"5319_CR31","unstructured":"Health A. PPVF version 1.0 methodology report. Avalere Health; 2017."},{"issue":"4","key":"5319_CR32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/hiv.13756","volume":"26","author":"T Hu","year":"2025","unstructured":"Hu T, Yang S, Yu J, Yang Z, Jin Y, Zhu Z. Transitions in treatment: a systematic review and meta-aggregation of preferences and barriers in switching from oral to long-acting injectable antiretroviral therapy among people living with HIV and stakeholders. HIV Med. 2025;26(4):512\u201335.","journal-title":"HIV Med"},{"issue":"5","key":"5319_CR33","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s11524-023-00755-6","volume":"100","author":"AB Collins","year":"2023","unstructured":"Collins AB, Macon EC, Langdon K, Joseph R, Thomas A, Dogon C, et al. Perceptions of long-acting injectable antiretroviral therapy among people living with HIV who use drugs and service providers: a qualitative analysis in Rhode Island. J Urban Health. 2023;100(5):1062\u201373.","journal-title":"J Urban Health"},{"issue":"1","key":"5319_CR34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12879-023-08071-9","volume":"23","author":"L Slama","year":"2023","unstructured":"Slama L, Porcher R, Linard F, Chakvetadze C, Cros A, Carillon S, et al. Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users. BMC Infect Dis. 2023;23(1):98.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"5319_CR35","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.idnow.2022.01.010","volume":"52","author":"C Palacios","year":"2022","unstructured":"Palacios C, Wilpotte C, Adda A, Allaf S, Thibaut P, Chas J, et al. Expectations and acceptability of long-acting injectable antiretrovirals by patients living with HIV\/AIDS. Infect Dis Now. 2022;52(4):238\u20139.","journal-title":"Infect Dis Now"},{"issue":"4","key":"5319_CR36","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1007\/s10461-021-03483-7","volume":"26","author":"MM Philbin","year":"2022","unstructured":"Philbin MM, Bergen S, Parish C, Kerrigan D, Kinnard EN, Reed S, et al. Long-acting injectable ART and PrEP among women in six cities across the United States: a qualitative analysis of who would benefit the most. AIDS Behav. 2022;26(4):1260\u20139.","journal-title":"AIDS Behav"},{"issue":"8","key":"5319_CR37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1136\/sextrans-2020-054648","volume":"97","author":"B Akinwunmi","year":"2021","unstructured":"Akinwunmi B, Buchenberger D, Scherzer J, Bode M, Rizzini P, Vecchio F, et al. Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries. Sex Transm Infect. 2021;97(8):566\u201373.","journal-title":"Sex Transm Infect"},{"issue":"2","key":"5319_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/QAI.0000000000003781","volume":"101","author":"D Kerrigan","year":"2026","unstructured":"Kerrigan D, Ruiz C, Castonguay BJU, Rodriguez Gonzalez H, Mayer K, Fleming J, et al. Factors associated with preference for long-acting injectable versus daily oral antiretroviral therapy among people with HIV: findings from the SELIGO study. J Acquir Immune Defic Syndr. 2026;101(2):183\u201390.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"5319_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac293","volume":"9","author":"KA Christopoulos","year":"2022","unstructured":"Christopoulos KA, Colasanti J, Johnson MO, Diaz Tsuzuki M, Erguera XA, Flores R, et al. Are patients and their providers talking about long-acting injectable antiretroviral therapy? Penetration into clinical encounters at three U.S. care sites. Open Forum Infect Dis. 2022;9(7):ofac293.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"5319_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-016-1914-4","volume":"16","author":"V Cooper","year":"2016","unstructured":"Cooper V, Clatworthy J, Youssef E, Llewellyn C, Miners A, Lagarde M, et al. Which aspects of health care are most valued by people living with HIV in high-income countries? A systematic review. BMC Health Serv Res. 2016;16(1):677.","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"5319_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208486","volume":"13","author":"ML Greene","year":"2018","unstructured":"Greene ML, Tan JY, Weiser SD, Christopoulos K, Shiels M, O\u2019Hollaren A, et al. Patient and provider perceptions of a comprehensive care program for HIV-positive adults over 50 years of age: the formation of the golden compass HIV and aging care program in San Francisco. PLoS ONE. 2018;13(12):e0208486.","journal-title":"PLoS ONE"},{"issue":"Suppl 4","key":"5319_CR42","doi-asserted-by":"publisher","first-page":"e25978","DOI":"10.1002\/jia2.25978","volume":"25","author":"K Murzin","year":"2022","unstructured":"Murzin K, Racz E, Behrens DM, Conway T, Da Silva G, Fitzpatrick E, et al. We can hardly even do it nowadays. So, what\u2019s going to happen in 5 years from now, 10 years from now?\" The health and community care and support needs and preferences of older people living with HIV in Ontario, Canada: a qualitative study. J Int AIDS Soc. 2022;25(Suppl 4):e25978.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"5319_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-11698-5","volume":"21","author":"Z Yang","year":"2021","unstructured":"Yang Z, Zhu Z, Lizarondo L, Xing W, Han S, Hu H, et al. Experience of chronic noncommunicable disease in people living with HIV: a systematic review and meta-aggregation of qualitative studies. BMC Public Health. 2021;21(1):1651.","journal-title":"BMC Public Health"},{"issue":"2","key":"5319_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.70082","volume":"29","author":"XA Erguera","year":"2026","unstructured":"Erguera XA, Smith MB, Pareek P, Dawdani A, Dance KV, Walker RS, et al. Optimizing the patient journey: insights from early implementation of long-acting cabotegravir and rilpivirine in four urban Ryan White-funded clinics in the United States. J Int AIDS Soc. 2026;29(2):e70082.","journal-title":"J Int AIDS Soc"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05319-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-026-05319-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05319-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:43:44Z","timestamp":1791247424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-026-05319-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":44,"alternative-id":["5319"],"URL":"https:\/\/doi.org\/10.1007\/s10461-026-05319-8","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"18 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CM is a cofounder of YOJO LLC, a software platform company. YOJO LLC did not support any work reported in this article. NLO has received consulting fees from ViiV Healthcare and Gilead Sciences. All other coauthors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed by the Duke University Institutional Review Board and was determined to be exempt from further review.","order":2,"name":"Ethics","label":"Research Involving Human Participants","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Verbal informed consent was obtained from all participants prior to participation, including consent for interview and audio recording, as approved by the IRB.","order":3,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}